Enanta Pharmaceuticals
ENTA
148 hedge funds and large institutions have $824M invested in Enanta Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 14 closing their positions.
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
38% more capital invested
Capital invested by funds: $598M → $824M (+$226M)
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
17% more funds holding
Funds holding: 127 → 148 (+21)
6.43% more ownership
Funds ownership: 66.95% → 73.38% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.5M |
| 3 |
Millennium Management
New York
|
+$11.1M |
| 4 |
First Manhattan
New York
|
+$6.87M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$8.59M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.86M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.85M |
| 4 |
KAM
Krensavage Asset Management
New York
|
-$7.36M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.68M |
ENTA Hedge Fund Activity: Q4 2017 in Review
148 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2017, worth a combined $824M — up 38% from $598M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ENTA positions and 14 closed out — a net gain of 21 holders — while 52 added to existing stakes and 40 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $25.7M. The largest seller was Stonepine Capital Management, cutting an estimated $8.59M.
- 148 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2017, up from 127 in Q3 2017.
- Funds reported $824M of Enanta Pharmaceuticals stock for Q4 2017, up 38% quarter-over-quarter.
- 35 funds opened new Enanta Pharmaceuticals positions in Q4 2017 and 14 closed out, a net change of +21 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2017 was Farallon Capital Management, an estimated $25.7M added.
- The largest Enanta Pharmaceuticals seller in Q4 2017 was Stonepine Capital Management, an estimated $8.59M sold.
Based on aggregated 13F filings for Q4 2017.